NCT03755557View on ClinicalTrials.gov

Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray

PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

April 5, 2019

Study Completion Date

April 5, 2019

Conditions
Allergic RhinitisAllergic ConjunctivitisHayfever
Interventions
DRUG

Rhinocort

Application of a nasal spray

DRUG

Budesolv

Application of a nasal spray

OTHER

Placebo

Application of a nasal spray

Trial Locations (1)

1140

Vienna Challenge Chamber, Vienna

Sponsors
All Listed Sponsors
lead

Marinomed Biotech AG

INDUSTRY

NCT03755557 - Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray | Biotech Hunter | Biotech Hunter